GoodRx Forecasts Q2 Revenue Of ~$200 Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx預測第二季度收入約爲200美元,而市場預期爲1.9957億美元,調整後的息稅折舊攤銷前利潤率在30%的低區間內
GoodRx Forecasts Q2 Revenue Of ~$200 Versus Consensus Of $199.57M, With Adjusted EBITDA Margin In Low Thirty-Percent Range
GoodRx預測第二季度收入約爲200美元,而市場預期爲1.9957億美元,調整後的息稅折舊攤銷前利潤率在30%的低區間內
使用瀏覽器的分享功能,分享給你的好友吧